{"id":11488,"date":"2020-11-20T18:02:39","date_gmt":"2020-11-20T23:02:39","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=11488"},"modified":"2022-11-14T17:17:52","modified_gmt":"2022-11-14T22:17:52","slug":"fda-approval","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/fr\/2020\/11\/20\/fda-approval\/","title":{"rendered":"Le jour est arriv\u00e9 : l\u2019approbation par la FDA du tout premier traitement contre la prog\u00e9ria !"},"content":{"rendered":"<p>[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.16\u2033 global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.16\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=&quot;{}&quot; custom_padding__hover=&quot;|||&quot;][et_pb_text admin_label=&quot;FDA&quot; _builder_version=&quot;4.18.1&quot; background_size=&quot;initial&quot; background_position=&quot;top_left&quot; background_repeat=&quot;repeat&quot; hover_enabled=&quot;0&quot; global_colors_info=&quot;{}&quot; sticky_enabled=&quot;0&quot;]<\/p>\n<p style=\"font-weight: 400;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11496 size-medium alignleft\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/FDA-page-169x300.jpg\" alt=\"\" width=\"169\" height=\"300\" srcset=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/FDA-page-169x300.jpg 169w, https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/FDA-page.jpg 300w\" sizes=\"(max-width: 169px) 100vw, 169px\" \/><\/strong>Derni\u00e8res nouvelles passionnantes ! Le 20 novembre 2020, PRF a accompli une partie importante de sa mission : <strong>Le lonafarnib, le tout premier traitement contre la prog\u00e9ria, a re\u00e7u l&#039;approbation de la FDA<\/strong>.<\/p>\n<p>La prog\u00e9ria touche d\u00e9sormais moins de\u00a0<strong>5% des maladies rares avec un traitement approuv\u00e9 par la FDA.*\u00a0<\/strong>Aux \u00c9tats-Unis, les enfants et les jeunes adultes atteints de prog\u00e9ria peuvent d\u00e9sormais acc\u00e9der au lonafarnib sur ordonnance, plut\u00f4t que par le biais d\u2019un essai clinique.<\/p>\n<p>Cette \u00e9tape historique a \u00e9t\u00e9 franchie gr\u00e2ce \u00e0 13 ann\u00e9es de recherche acharn\u00e9e impliquant <a href=\"https:\/\/www.progeriaresearch.org\/fr\/clinical-trials\/\">quatre essais cliniques<\/a>, le tout coordonn\u00e9 par PRF, rendu possible par les enfants courageux et leurs familles, et financ\u00e9 par vous, la merveilleuse communaut\u00e9 de donateurs de PRF.<\/p>\n<p>Nous sommes \u00e9galement reconnaissants aux \u00e9quipes de recherche de renomm\u00e9e mondiale sur la prog\u00e9ria du Boston Children&#039;s Hospital, du Hasbro Children&#039;s Hospital, du Brigham and Women&#039;s Hospital, de l&#039;universit\u00e9 Brown, de l&#039;universit\u00e9 de Boston et des National Institutes of Health. Les partenaires pharmaceutiques qui ont fourni gratuitement du lonafarnib aux essais cliniques soutenus par le PRF ont \u00e9galement jou\u00e9 un r\u00f4le crucial, notamment Shering-Plough, Merck** (connu sous le nom de MSD en dehors des \u00c9tats-Unis et du Canada) et Eiger BioPharmaceuticals, pour leur contribution \u00e0 l&#039;avancement des progr\u00e8s de la recherche sur la prog\u00e9ria vers ces nouveaux sommets extraordinaires.<\/p>\n<p>Nos partenaires chez Eiger s&#039;engagent \u00e0 fournir un acc\u00e8s continu au lonafarnib aux patients atteints de prog\u00e9ria et de laminopathies prog\u00e9ro\u00efdes d\u00e9ficientes en traitement dans le monde entier, et ils ont mis en place des services pour soutenir l&#039;acc\u00e8s au lonafarnib par <em>Eiger OneCare, <\/em>L&#039;examen du lonafarnib par l&#039;Agence europ\u00e9enne des m\u00e9dicaments (EMA) est toujours en cours, une d\u00e9cision sur l&#039;approbation de l&#039;EMA \u00e9tant attendue au second semestre 2021.<\/p>\n<p>MERCI \u00c0 TOUS pour votre soutien \u00e0 la recherche qui nous a amen\u00e9s \u00e0 ce point crucial. Votre soutien continu nous permet \u00e9galement de continuer \u00e0 progresser vers la d\u00e9couverte d&#039;un rem\u00e8de pour ces enfants extraordinaires.<\/p>\n<p><strong>Quelle fa\u00e7on vraiment remarquable de commencer la p\u00e9riode des f\u00eates et de terminer cette incroyable<\/strong><strong> stimulant<\/strong> <strong>ann\u00e9e.<\/strong><\/p>\n<p><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/PRF-Press-Release-Zokinvy-FDA-Approval-FINAL.pdf\" rel=\"attachment wp-att-11508\">Cliquez ici pour notre communiqu\u00e9 de presse<\/a> qui fournit plus de d\u00e9tails sur cette nouvelle historique.<\/p>\n<p>*300 maladies rares qui ont un traitement approuv\u00e9 par la FDA (<a href=\"https:\/\/www.rarediseases.info.nih.gov\/diseases\/FDS-orphan-drugs)\/7,000\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.rarediseases.info.nih.gov\/diseases\/FDS-orphan-drugs)\/7,000&amp;source=gmail&amp;ust=1617209033114000&amp;usg=AFQjCNGl8GC3JC7PBWSWbj-cHfQgWmhudQ\">https:\/\/www.rarediseases.info.nih.gov\/diseases\/FDS-orphan-drugs)\/7,000<\/a>\u00a0maladies rares pour lesquelles la base mol\u00e9culaire est connue (<a href=\"http:\/\/www.omim.org\/\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=http:\/\/www.OMIM.org&amp;source=gmail&amp;ust=1617209033114000&amp;usg=AFQjCNG6pGE6IFhDHqW6SGpJ5A14AfU7ZA\">www.OMIM.org<\/a>) =4.2%<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u201d4.16\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text admin_label=\u201dFDA\u201d _builder_version=\u201d4.16\u2033 text_font_size=\u201d13px\u201d background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d]<\/p>\n<p><span>**\u00a0<\/span><span>PRF tient \u00e0 remercier les scientifiques de Schering-Plough \/ Merck R&amp;D pour leurs contributions essentielles qui ont soutenu<span class=\"m_-8175828865577728923apple-converted-space\">\u00a0<\/span>\u00e0 la fois l&#039;\u00e9valuation du lonafarnib dans les mod\u00e8les pr\u00e9cliniques de HGPS et les \u00e9tudes cliniques chez les patients atteints de prog\u00e9ria.<span class=\"m_-8175828865577728923apple-converted-space\">\u00a0<\/span>L&#039;\u00e9quipe, dirig\u00e9e par W. Robert Bishop, John Piwinski, Cecil Pickett et Catherine Strader, a soutenu les \u00e9tudes pharmacocin\u00e9tiques\/pharmacodynamiques, optimis\u00e9 la formulation des m\u00e9dicaments et assur\u00e9 un approvisionnement ad\u00e9quat en m\u00e9dicaments tout au long de ces \u00e9tudes. Les membres de cette \u00e9quipe \u00e9taient : Susan Arbuck,<span class=\"m_-8175828865577728923apple-converted-space\">\u00a0<\/span><\/span><span>Art Bertelsen, Alan Cooper, Emily Frank, David Harris, Georgianna Harris,<span class=\"m_-8175828865577728923apple-converted-space\">\u00a0<\/span>Paul Kirschmeier, Ming Liu, Jin-Keon Pai, Robert Patton, Paul Statkevich, Greg Szpunar, Bohdan Yaremko, Paul Zavodny et Yali Zhu.<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>Nous sommes ravis d&#039;annoncer qu&#039;aujourd&#039;hui, nous avons accompli une partie importante de la mission du PRF : le lonafarnib, le tout premier traitement contre la prog\u00e9ria, a re\u00e7u l&#039;approbation de la FDA. <\/p>","protected":false},"author":2,"featured_media":11491,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,1],"tags":[],"class_list":["post-11488","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The day has come: FDA approval for first-ever Progeria treatment! - The Progeria Research Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/fr\/2020\/11\/20\/fda-approval\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The day has come: FDA approval for first-ever Progeria treatment! - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"We\u2019re thrilled to announce that today, we achieved an important piece of PRF\u2019s mission: lonafarnib, the first-ever treatment for Progeria, has been granted FDA approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/fr\/2020\/11\/20\/fda-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-20T23:02:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-14T22:17:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"199\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"The day has come: FDA approval for first-ever Progeria treatment!\",\"datePublished\":\"2020-11-20T23:02:39+00:00\",\"dateModified\":\"2022-11-14T22:17:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/\"},\"wordCount\":593,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg\",\"articleSection\":[\"News\",\"Uncategorized\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/\",\"name\":\"The day has come: FDA approval for first-ever Progeria treatment! - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg\",\"datePublished\":\"2020-11-20T23:02:39+00:00\",\"dateModified\":\"2022-11-14T22:17:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg\",\"width\":200,\"height\":199},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The day has come: FDA approval for first-ever Progeria treatment!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/fr\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Le jour tant attendu est arriv\u00e9\u00a0: la FDA a approuv\u00e9 le tout premier traitement contre la prog\u00e9ria\u00a0! \u2013 La Fondation pour la recherche sur la prog\u00e9ria","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/fr\/2020\/11\/20\/fda-approval\/","og_locale":"fr_FR","og_type":"article","og_title":"The day has come: FDA approval for first-ever Progeria treatment! - The Progeria Research Foundation","og_description":"We\u2019re thrilled to announce that today, we achieved an important piece of PRF\u2019s mission: lonafarnib, the first-ever treatment for Progeria, has been granted FDA approval.","og_url":"https:\/\/www.progeriaresearch.org\/fr\/2020\/11\/20\/fda-approval\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2020-11-20T23:02:39+00:00","article_modified_time":"2022-11-14T22:17:52+00:00","og_image":[{"width":200,"height":199,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"The day has come: FDA approval for first-ever Progeria treatment!","datePublished":"2020-11-20T23:02:39+00:00","dateModified":"2022-11-14T22:17:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/"},"wordCount":593,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg","articleSection":["News","Uncategorized"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/","url":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/","name":"Le jour tant attendu est arriv\u00e9\u00a0: la FDA a approuv\u00e9 le tout premier traitement contre la prog\u00e9ria\u00a0! \u2013 La Fondation pour la recherche sur la prog\u00e9ria","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg","datePublished":"2020-11-20T23:02:39+00:00","dateModified":"2022-11-14T22:17:52+00:00","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg","width":200,"height":199},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"The day has come: FDA approval for first-ever Progeria treatment!"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"La Fondation de recherche sur la prog\u00e9ria","description":"Pour les enfants \u2665 Pour la gu\u00e9rison","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"La Fondation de recherche sur la prog\u00e9ria","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"Karen Betournay","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/fr\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/posts\/11488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/comments?post=11488"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/posts\/11488\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/media\/11491"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/media?parent=11488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/categories?post=11488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/fr\/wp-json\/wp\/v2\/tags?post=11488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}